Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Immune Checkpoint Inhibitors market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Immune Checkpoint Inhibitors market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.
Segmented by Category
PD-1/PD-L1
CTLA-4
Segmented by End User/Segment
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia
Key manufacturers included in this survey
Sorrento Therapeutics
Seattle Genetics
Roche / Genentech
Pfizer
NewLink Genetics
Merck & Co.
MacroGenics
Innate Pharma
Incyte Corporation
Immutep
GlaxoSmithKline
GITR, Inc
CureTech
Celldex Therapeutics
Bristol Myer Squibb
AstraZeneca
ArGEN-X
Table of Contents1 Product Introduction and Overview 1.1 Product Definition 1.2 Product Specification 1.3 Global Market Overview 1.3.1 Global Immune Checkpoint Inhibitors Market Status and Forecast (2016-2027) 1.3.2 Global Immune Checkpoint Inhibitors Sales Value CAGR by Region 1.4 Market Drivers, Inhibitors 1.4.1 Market Drivers 1.4.2 Market Inhibitors 1.4.3 COVID-19 Impact Analysis2 Global Immune Checkpoint Inhibitors Supply by Company 2.1 Global Immune Checkpoint Inhibitors Sales Volume by Company 2.2 Global Immune Checkpoint Inhibitors Sales Value by Company 2.3 Global Immune Checkpoint Inhibitors Price by Company 2.4 Immune Checkpoint Inhibitors Production Location and Sales Area of Main Manufacturers 2.5 Trend of Concentration Rate3 Global and Regional Immune Checkpoint Inhibitors Market Status by Category 3.1 Immune Checkpoint Inhibitors Category Introduction 3.1.1 PD-1/PD-L1 3.1.2 CTLA-4 3.2 Global Immune Checkpoint Inhibitors Market by Category 3.2.1 Global Immune Checkpoint Inhibitors Sales Volume by Category (2016-2021) 3.2.2 Global Immune Checkpoint Inhibitors Sales Value by Category (2016-2021) 3.2.3 Global Immune Checkpoint Inhibitors Price by Category (2016-2021) 3.3 North America: by Category 3.4 Europe: by Category 3.5 Asia Pacific: by Category 3.6 Central & South America: by Category 3.7 Middle East & Africa: by Category4 Global and Regional Immune Checkpoint Inhibitors Market Status by End User/Segment 4.1 Immune Checkpoint Inhibitors Segment by End User/Segment 4.1.1 Lung Cancer 4.1.2 Colorectal Cancer 4.1.3 Breast Cancer 4.1.4 Prostate Cancer 4.1.5 Melanoma 4.1.6 Blood Cancer 4.1.7 Other 4.2 Global Immune Checkpoint Inhibitors Market by End User/Segment 4.2.1 Global Immune Checkpoint Inhibitors Sales Volume by End User/Segment (2016-2021) 4.2.2 Global Immune Checkpoint Inhibitors Sales Value by End User/Segment (2016-2021) 4.2.3 Global Immune Checkpoint Inhibitors Price by End User/Segment (2016-2021) 4.3 North America: by End User/Segment 4.4 Europe: by End User/Segment 4.5 Asia Pacific: by End User/Segment 4.6 Central & South America: by End User/Segment 4.7 Middle East & Africa: by End User/Segment5 Global Immune Checkpoint Inhibitors Market Status by Region 5.1 Global Immune Checkpoint Inhibitors Market by Region 5.1.1 Global Immune Checkpoint Inhibitors Sales Volume by Region 5.1.2 Global Immune Checkpoint Inhibitors Sales Value by Region 5.2 North America Immune Checkpoint Inhibitors Market Status 5.3 Europe Immune Checkpoint Inhibitors Market Status 5.4 Asia Pacific Immune Checkpoint Inhibitors Market Status 5.5 Central & South America Immune Checkpoint Inhibitors Market Status 5.6 Middle East & Africa Immune Checkpoint Inhibitors Market Status6 North America Immune Checkpoint Inhibitors Market Status 6.1 North America Immune Checkpoint Inhibitors Market by Country 6.1.1 North America Immune Checkpoint Inhibitors Sales Volume by Country (2016-2021) 6.1.2 North America Immune Checkpoint Inhibitors Sales Value by Country (2016-2021) 6.2 United States 6.3 Canada 6.4 Mexico7 Europe Immune Checkpoint Inhibitors Market Status 7.1 Europe Immune Checkpoint Inhibitors Market by Country 7.1.1 Europe Immune Checkpoint Inhibitors Sales Volume by Country (2016-2021) 7.1.2 Europe Immune Checkpoint Inhibitors Sales Value by Country (2016-2021) 7.2 Germany 7.3 France 7.4 UK 7.5 Italy 7.6 Russia 7.7 Spain8 Asia Pacific Immune Checkpoint Inhibitors Market Status 8.1 Asia Pacific Immune Checkpoint Inhibitors Market by Country 8.1.1 Asia Pacific Immune Checkpoint Inhibitors Sales Volume by Country (2016-2021) 8.1.2 Asia Pacific Immune Checkpoint Inhibitors Sales Value by Country (2016-2021) 8.2 China 8.3 Japan 8.4 Korea 8.5 Southeast Asia 8.6 India 8.7 Australasia9 Central & South America Immune Checkpoint Inhibitors Market Status 9.1 Central & South America Immune Checkpoint Inhibitors Market by Country 9.1.1 Central & South America Immune Checkpoint Inhibitors Sales Volume by Country (2016-2021) 9.1.2 Central & South America Immune Checkpoint Inhibitors Sales Value by Country (2016-2021) 9.2 Brazil 9.3 Argentina 9.4 Colombia10 Middle East & Africa Immune Checkpoint Inhibitors Market Status 10.1 Middle East & Africa Immune Checkpoint Inhibitors Market by Country 10.1.1 Middle East & Africa Immune Checkpoint Inhibitors Sales Volume by Country (2016-2021) 10.1.2 Middle East & Africa Immune Checkpoint Inhibitors Sales Value by Country (2016-2021) 10.2 Iran 10.3 Israel 10.4 Turkey 10.5 South Africa 10.8 Saudi Arabia11 Supply Chain and Manufacturing Cost Analysis 11.1 Supply Chain Analysis 11.2 Production Process Chart Analysis 11.3 Raw Materials and Key Suppliers Analysis 11.3.1 Raw Materials Introduction 11.3.2 Raw Materials Key Suppliers List 11.4 Immune Checkpoint Inhibitors Manufacturing Cost Analysis 11.5 Immune Checkpoint Inhibitors Sales Channel and Distributors Analysis 11.5.1 Immune Checkpoint Inhibitors Sales Channel 11.5.2 Immune Checkpoint Inhibitors Distributors 11.6 Immune Checkpoint Inhibitors Downstream Major Buyers12 Global Immune Checkpoint Inhibitors Market Forecast by Category and by End User/Segment 12.1 Global Immune Checkpoint Inhibitors Sales Volume and Sales Value Forecast (2022-2027) 12.2 Global Immune Checkpoint Inhibitors Forecast by Category 12.2.1 Global Immune Checkpoint Inhibitors Sales Volume Forecast by Category 12.2.2 Global Immune Checkpoint Inhibitors Sales Value Forecast by Category 12.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Category 12.3 Global Immune Checkpoint Inhibitors Forecast by End User/Segment 12.3.1 Global Immune Checkpoint Inhibitors Sales Volume Forecast by End User/Segment 12.3.2 Global Immune Checkpoint Inhibitors Sales Value Forecast by End User/Segment 12.3.3 Global Immune Checkpoint Inhibitors Price Forecast by End User/Segment13 Global Immune Checkpoint Inhibitors Market Forecast by Region/Country 13.1 Global Immune Checkpoint Inhibitors Market Forecast by Region (2022-2027) 13.1.1 Global Immune Checkpoint Inhibitors Sales Volume Forecast by Region (2022-2027) 13.1.2 Global Immune Checkpoint Inhibitors Sales Value Forecast by Region (2022-2027) 13.2 North America Market Forecast 13.3 Europe Market Forecast 13.4 Asia Pacific Market Forecast 13.5 Central & South America Market Forecast 13.6 Middle East & Africa Market Forecast14 Key Participants Company Information 14.1 Sorrento Therapeutics 14.1.1 Company Information 14.1.2 Immune Checkpoint Inhibitors Product Introduction 14.1.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.1.4 SWOT Analysis 14.2 Seattle Genetics 14.2.1 Company Information 14.2.2 Immune Checkpoint Inhibitors Product Introduction 14.2.3 Seattle Genetics Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.2.4 SWOT Analysis 14.3 Roche / Genentech 14.3.1 Company Information 14.3.2 Immune Checkpoint Inhibitors Product Introduction 14.3.3 Roche / Genentech Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.3.4 SWOT Analysis 14.4 Pfizer 14.4.1 Company Information 14.4.2 Immune Checkpoint Inhibitors Product Introduction 14.4.3 Pfizer Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.4.4 SWOT Analysis 14.5 NewLink Genetics 14.5.1 Company Information 14.5.2 Immune Checkpoint Inhibitors Product Introduction 14.5.3 NewLink Genetics Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.5.4 SWOT Analysis 14.6 Merck & Co. 14.6.1 Company Information 14.6.2 Immune Checkpoint Inhibitors Product Introduction 14.6.3 Merck & Co. Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.6.4 SWOT Analysis 14.7 MacroGenics 14.7.1 Company Information 14.7.2 Immune Checkpoint Inhibitors Product Introduction 14.7.3 MacroGenics Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.7.4 SWOT Analysis 14.8 Innate Pharma 14.8.1 Company Information 14.8.2 Immune Checkpoint Inhibitors Product Introduction 14.8.3 Innate Pharma Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.8.4 SWOT Analysis 14.9 Incyte Corporation 14.9.1 Company Information 14.9.2 Immune Checkpoint Inhibitors Product Introduction 14.9.3 Incyte Corporation Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.9.4 SWOT Analysis 14.10 Immutep 14.10.1 Company Information 14.10.2 Immune Checkpoint Inhibitors Product Introduction 14.10.3 Immutep Immune Checkpoint Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.10.4 SWOT Analysis 14.11 GlaxoSmithKline 14.12 GITR, Inc 14.13 CureTech 14.14 Celldex Therapeutics 14.15 Bristol Myer Squibb 14.16 AstraZeneca 14.17 ArGEN-X15 Conclusion16 Methodology